Form 4 · Filed Jul 9, 2026, 08:54 PM UTC
SNDX/Syndax Pharmaceuticals Inc
Metzger Michael A — Chief Executive Officer
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
3 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | M | other | 32,375 | $6 | $206,553 | 517,218 |
| Jul 8, 2026 | S | sell | 32,375 | $24 | $784,776 | 484,843 |
| Jul 8, 2026 | M | other | 32,375 | — | — | 0 |
Source: SEC EDGAR raw filing ↗ · Accession 0001193125-26-299803